Rowan Kuiper
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Oncology top 5%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
Papers in
- Hematology 33
- Multiple Myeloma Research and Treatments 33
- Oncology 10
- Peptidase Inhibition and Analysis 6
- Cancer Treatment and Pharmacology 3
- Co-authors
- Pieter Sonneveld (28 shared papers)Mark van Duin (23 shared papers)Bronno van der Holt (15 shared papers)Hartmut Goldschmidt (10 shared papers)Laila el Jarari (8 shared papers)Annemiek Broyl (9 shared papers)Gareth John Morgan (9 shared papers)Yvonne de Knegt (7 shared papers)
- Journals
- Blood (13 papers)Leukemia (2 papers)Blood Cancer Journal (2 papers)Blood Advances (2 papers)Haematologica (2 papers)
- Partner nations
- NetherlandsUnited StatesGermany
In The Last Decade
Rowan Kuiper
34 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 69
- Hematology 998
- Oncology 560
- Molecular Biology 842
- Genetics 103
- Cancer Research 100
Countries citing papers authored by Rowan Kuiper
This map shows the geographic impact of Rowan Kuiper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rowan Kuiper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rowan Kuiper more than expected).
Fields of papers citing papers by Rowan Kuiper
This network shows the impact of papers produced by Rowan Kuiper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rowan Kuiper. The network helps show where Rowan Kuiper may publish in the future.
Co-authors
The 25 scholars most cited alongside Rowan Kuiper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 237 | |
| 2 | 2010 | 194 | |
| 3 | 2016 | 149 | |
| 4 | 2021 | 148 | |
| 5 | 2012 | 114 | |
| 6 | 2015 | 97 | |
| 7 | 2018 | 97 | |
| 8 | 2011 | 52 | |
| 9 | 2011 | 49 | |
| 10 | 2008 | 44 | |
| 11 | 2017 | 38 | |
| 12 | 2016 | 37 | |
| 13 | 2018 | 34 | |
| 14 | 2022 | 27 | |
| 15 | 2020 | 26 | |
| 16 | 2020 | 15 | |
| 17 | 2021 | 14 | |
| 18 | 2019 | 14 | |
| 19 | 2017 | 11 | |
| 20 | 2014 | 6 |
About Rowan Kuiper
Rowan Kuiper is a scholar working on Hematology, Oncology, Molecular Biology, Cancer Research and Pathology and Forensic Medicine, having authored 38 papers that have together received 1.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (33 papers), Protein Degradation and Inhibitors (16 papers), Ubiquitin and proteasome pathways (8 papers), Peptidase Inhibition and Analysis (6 papers), Cancer Treatment and Pharmacology (3 papers), Glycosylation and Glycoproteins Research (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and MicroRNA in disease regulation (2 papers). The work is most often cited by research in Hematology (998 citations), Oncology (560 citations), Molecular Biology (842 citations), Genetics (103 citations) and Cancer Research (100 citations). Rowan Kuiper has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Pieter Sonneveld, Mark van Duin, Bronno van der Holt, Hartmut Goldschmidt, Laila el Jarari, Annemiek Broyl, Gareth John Morgan, Yvonne de Knegt, Henk M. Lokhorst and Martin H. van Vliet. Their work appears in journals such as Blood, Leukemia, Blood Cancer Journal, Blood Advances and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.